Abstract:Aim: Recent progress in cancer immunotherapy has shown its promise and prompted researchers to develop novel therapeutic strategies. Dendritic cells (DCs) are professional antigen-presenting cells crucial for initiating adaptive anti-tumor immunity, therefore a promising target for cancer treatment. Here, anti-tumor activities of DC-targeting chemokines were explored in murine colorectal tumor models. Methods: The correlation of chemokine messenger RNA (mRNA) expression with DC markers was analyzed using The Cancer Genome Atlas (TCGA) dataset. Murine colorectal tumor cell lines (CT26 and MC38) stably overexpressing mouse C-C motif chemokine ligand 3 (CCL3), CCL19, CCL21, and X-C motif chemokine ligand 1 (XCL1) were established by lentiviral transduction. The effect of chemokines on tumor cell proliferation/survival was evaluated in vitro by cell counting kit-8 (CCK-8) assay and colony formation assay. Syngeneic subcutaneous tumor models were used to study the effects of these chemokines on tumor growth. Ki-67 expression in tumors was examined by immunohistochemistry. Immune cells in the tumor microenvironment (TME) and lymph nodes were analyzed by flow cytometry. Results: Expression of the four chemokines was positively correlated with the two DC markers [integrin alpha X (ITGAX) and CLEC9A] in human colorectal tumor samples. Tumoral overexpression of DC-targeting chemokines had little or no effect on tumor cell proliferation/survival in vitro while significantly suppressing tumor growth in vivo. Fluorescence-activated cell sorting (FACS) analysis showed that CCL19, CCL21, and XCL1 boosted the ratios of DCs and T cells in CD45+ leukocytes while CCL3 increased the percentage of CD45+ leukocytes in total cells in MC38 tumor. XCL1 had an additional positive effect on antigen uptake by DCs in the TME and antigen transfer to tumor-draining lymph nodes. Conclusions: CCL3, CCL19, CCL21, and XCL1 exhibited potent anti-tumor activities in vivo, although they might differentially regulate immune cells in the TME and antigen transfer to lymph nodes.

Dendritic Cell-Targeting Chemokines Inhibit Colorectal Cancer Progression

CXCL8 Associated Dendritic Cell Activation Marker Expression and Recruitment as Indicators of Favorable Outcomes in Colorectal Cancer

Dendritic Cells Loaded with CD44+ CT-26 Colon Cell Lysate Evoke Potent Antitumor Immune Responses.

CCL3 Promotes Proliferation of Colorectal Cancer

Anti-tumor activity of chemokine is affected by both kinds of tumors and the activation state of the host's immune system: implications for chemokine-based cancer immunotherapy.

Synergistic effect of radiotherapy and dendritic-cell-based immunotherapy via miR-15b-5p regulation in a colon carcinoma mouse model

CCL19+ Dendritic Cells Potentiate Clinical Benefit of Anti-Pd-(l)1 Immunotherapy in Triple-Negative Breast Cancer

Analysis of the Clinical Efficacy of Dendritic Cell –cytokine Induced Killer Cell-based Adoptive Immunotherapy for Colorectal Cancer

Targeting Tumor-Expressing CCR6 Inhibits Colorectal Cancer Progression in Mice (127.44)

Overexpressed Cxcr4 And Ccr7 On The Surface Of Nk92 Cell Have Improved Migration And Anti-Tumor Activity In Human Colon Tumor Model

Influence of Regulatory T Cells on Antitumor Activity of Dendritic Cells-Cytokine Induced Killer Cells in Gastric Cancer Xenograft Models

Clinical Effects of Autologous Dendritic Cells Combined with Cytokine-Induced Killer Cells Followed by Chemotherapy in Treating Patients with Advanced Colorectal Cancer: a Prospective Study

Antitumor Efficacy of CC Motif Chemokine Ligand 19 in Colorectal Cancer

CXCL13 Modulates Immunoactive Tumor Microenvironment and Improves Prognosis in Colorectal Cancer

CCL3 Promotes Proliferation of Colorectal Cancer Related with TRAF6/NF-κB Molecular Pathway

Chemokines and Their Receptors Promoting the Recruitment of Myeloid-Derived Suppressor Cells into the Tumor.

Myeloid-Derived Suppressor Cells: A New and Pivotal Player in Colorectal Cancer Progression

NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control

Targeting the CCL2/CCR2 Axis in Cancer Immunotherapy: One Stone, Three Birds?

The functional roles of chemokines and chemokine receptors in colorectal cancer progression

Interaction of the chemokines I-TAC (CXCL11) and SDF-1 (CXCL12) in the regulation of tumor angiogenesis of colorectal cancer